The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses
Open accessAbstract
Recent studies on gene molecular profiling using cDNA microarray in a relatively small series of breast cancer have identified biologically distinct groups with apparent clinical and prognostic relevance. The validation of such new taxonomies should be confirmed on larger series of cases prior to acceptance in clinical practice. The development of tissue microarray (TMA) technology provides methodology for high‐throughput concomitant analyses of multiple proteins on large numbers of archival tumour samples. In our study, we have used immunohistochemistry techniques applied to TMA preparations of 1,076 cases of invasive breast cancer to study the combined protein expression profiles of a large panel of well‐characterized commercially available biomarkers related to epithelial cell lineage, differentiation, hormone and growth factor receptors and gene products known to be altered in some forms of breast cancer. Using hierarchical clustering methodology, 5 groups with distinct patterns of protein expression were identified. A sixth group of only 4 cases was also identified but deemed too small for further detailed assessment. Further analysis of these clusters was performed using multiple layer perceptron (MLP)‐artificial neural network (ANN) with a back propagation algorithm to identify key biomarkers driving the membership of each group. We have identified 2 large groups by their expression of luminal epithelial cell phenotypic characteristics, hormone receptors positivity, absence of basal epithelial phenotype characteristics and lack of c‐erbB‐2 protein overexpression. Two additional groups were characterized by high c‐erbB‐2 positivity and negative or weak hormone receptors expression but showed differences in MUC1 and E‐cadherin expression. The final group was characterized by strong basal epithelial characteristics, p53 positivity, absent hormone receptors and weak to low luminal epithelial cytokeratin expression. In addition, we have identified significant differences between clusters identified in this series with respect to established prognostic factors including tumour grade, size and histologic tumour type as well as differences in patient outcomes. The different protein expression profiles identified in our study confirm the biologic heterogeneity of breast cancer and demonstrate the clinical relevance of classification in this manner. These observations could form the basis of revision of existing traditional classification systems for breast cancer. © 2005 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“It has a therapeutic value in selecting cases more likely to be responsive to cerbB-2-directed immunotherapy.(48) In our series, c-erbB-2 was a driving marker into 2 groups (groups 3 and 6).”
BackgroundSørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
ELSTON, C. W., & ELLIS, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,175
Self-citationRepeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Pathological prognostic factors in breast cancer
Elston, C. (1999) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(99)00034-7 · Cited by 1,735
McCarty, K. S., MILLER, L. S., Cox, E. B., Konrath, J. G., & McCarty, K. S. (1985) · PubMed · Cited by 1,027
Cited by
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091
Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra1001389 · Cited by 4,157
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Tumor-Infiltrating CD8+Lymphocytes Predict Clinical Outcome in Breast Cancer
Mahmoud, S. M. A., Paish, E. C., Powe, D. G., Macmillan, R. D., Grainge, M. J., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5037 · Cited by 1,367
Self-citationPrognostic markers in triple‐negative breast cancer
Rakha, E. A., El‐Sayed, M. E., Green, A. R., Lee, A. H. S., Robertson, J. F., & Ellis, I. O. (2007) · Cancer · doi:10.1002/cncr.22381 · Cited by 1,283
Self-citationBasal-Like Breast Cancer: A Critical Review
Rakha, E. A., Reis-Filho, J. S., & Ellis, I. O. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1748 · Cited by 1,164
Self-citationBiological subtypes of breast cancer: Prognostic and therapeutic implications
Yersal, O. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.412 · Cited by 1,156
Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype
Sarrió, D., Rodriguez-Pinilla, S. M., Hardisson, D., Cano, A., Moreno-Bueno, G., & Palacios, J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2017 · Cited by 1,056
Breast cancer prognostic classification in the molecular era: the role of histological grade
Rakha, E. A., Reis-Filho, J. S., Baehner, F., Dabbs, D. J., Decker, T., Eusebi, V., Fox, S. B., Ichihara, S., Jacquemier, J., Lakhani, S. R., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2607 · Cited by 1,003
Self-citationMolecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?
Brenton, J. D., Carey, L. A., Ahmed, A. A., & Caldas, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3845 · Cited by 953
Epidemiology of basal-like breast cancer
Millikan, R. C., Newman, B., Tse, C.-K., Moorman, P. G., Conway, K., Smith, L. V., Labbok, M. H., Geradts, J., Bensen, J. T., Jackson, S., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9632-6 · Cited by 886
Triple negative tumours: a critical review
Reis‐Filho, J. S., & Tutt, A. N. J. (2008) · Histopathology · doi:10.1111/j.1365-2559.2007.02889.x · Cited by 884
Triple-negative breast cancer: therapeutic options
Cleator, S., Heller, W., & Coombes, R. C. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70074-8 · Cited by 882
Cuzick, J., Dowsett, M., Pineda, S., Wale, C., Salter, J., Quinn, E., Zabaglo, L., Mallon, E., Green, A. R., Ellis, I. O., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.2835 · Cited by 739
Self-citationTriple-negative breast cancer—current status and future directions
Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U., & Harbeck, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp492 · Cited by 687
BRCA1 dysfunction in sporadic basal-like breast cancer
Turner, N. C., Reis-Filho, J. S., Russell, A. M., Springall, R. J., Ryder, K., Steele, D., Savage, K., Gillett, C. E., Schmitt, F. C., Ashworth, A., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210014 · Cited by 573
Gene expression profiling of breast cell lines identifies potential new basal markers
Charafe-Jauffret, E., Ginestier, C., Monville, F., Finetti, P., Adélaïde, J., Cervera, N., Fekairi, S., Xerri, L., Jacquemier, J., Birnbaum, D., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209254 · Cited by 569
Tumor Heterogeneity in Breast Cancer
Turashvili, G., & Brogi, E. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00227 · Cited by 561
Elsheikh, S. E., Green, A. R., Rakha, E. A., Powe, D. G., Ahmed, R. A., Collins, H. M., Soria, D., Garibaldi, J. M., Paish, C. E., Ammar, A. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3907 · Cited by 511
Self-citationBasal-like breast cancer and the BRCA1 phenotype
Turner, N. C., & Reis-Filho, J. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209876 · Cited by 478
Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis
Stingl, J., & Caldas, C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2212 · Cited by 470
Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA
Lund, M. J., Trivers, K. F., Porter, P. L., Coates, R. J., Leyland-Jones, B., Brawley, O. W., Flagg, E. W., O’Regan, R. M., Gabram, S. G. A., & Eley, J. W. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9926-3 · Cited by 390
Chen, B., Yu, P., Chan, W. N., Xie, F., Zhang, Y., Liang, L., Leung, K. T., Lo, K. W., Yu, J., Tse, G. M. K., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01679-y · Cited by 420
Collins, L. C., Cole, K. S., Marotti, J. D., Hu, R., Schnitt, S. J., & Tamimi, R. M. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.54 · Cited by 387
Mirzoeva, O. K., Das, D., Heiser, L. M., Bhattacharya, S., Siwak, D., Gendelman, R., Bayani, N., Wang, N. J., Neve, R. M., Guan, Y., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3389 · Cited by 385
What is triple-negative breast cancer?
Irvin, W. J., & Carey, L. A. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.09.034 · Cited by 350
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
Corkery, B., Crown, J., Clynes, M., & O'Donovan, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn710 · Cited by 348
Linderholm, B. K., Hellborg, H., Johansson, U., Elmberger, G., Skoog, L., Lehtiö, J., & Lewensohn, R. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp062 · Cited by 347
Comparison of molecular phenotypes of ductal carcinoma in situand invasive breast cancer
Tamimi, R. M., Baer, H. J., Marotti, J., Galan, M., Galaburda, L., Fu, Y., Deitz, A. C., Connolly, J. L., Schnitt, S. J., Colditz, G. A., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr2128 · Cited by 343
Metaplastic breast carcinomas are basal‐like tumours
Reis‐Filho, J. S., Milanezi, F., Steele, D., Savage, K., Simpson, P. T., Nesland, J. M., Pereira, E. M., Lakhani, S. R., & Schmitt, F. C. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02467.x · Cited by 341
Triple negative breast cancer: unmet medical needs
Pal, S. K., Childs, B. H., & Pegram, M. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1293-1 · Cited by 322
Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors
Kwan, M. L., Kushi, L. H., Weltzien, E., Maring, B., Kutner, S. E., Fulton, R. S., Lee, M. M., Ambrosone, C. B., & Caan, B. J. (2009) · Breast Cancer Research · doi:10.1186/bcr2261 · Cited by 318
Tan, D. S. P., Marchió, C., Jones, R. L., Savage, K., Smith, I. E., Dowsett, M., & Reis-Filho, J. S. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9756-8 · Cited by 318
Dawson, S.-J., Makretsov, N., Blows, F. M., Driver, K. E., Provenzano, E., Le Quesne, J., Baglietto, L., Severi, G., Giles, G. G., McLean, C. A., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605736 · Cited by 317
Self-citationWalker, R. A. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02514.x · Cited by 316
Rakha, E., Putti, T., Abd El‐Rehim, D., Paish, C., Green, A., Powe, D., Lee, A., Robertson, J., & Ellis, I. (2006) · The Journal of Pathology · doi:10.1002/path.1916 · Cited by 311
Self-citationA new genome‐driven integrated classification of breast cancer and its implications
Dawson, S., Rueda, O. M., Aparicio, S., & Caldas, C. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.19 · Cited by 306
Fulford, L. G., Reis-Filho, J. S., Ryder, K., Jones, C., Gillett, C. E., Hanby, A., Easton, D., & Lakhani, S. R. (2007) · Breast Cancer Research · doi:10.1186/bcr1636 · Cited by 306
Integrated Profiling of Basal and Luminal Breast Cancers
Adélaïde, J., Finetti, P., Bekhouche, I., Repellini, L., Geneix, J., Sircoulomb, F., Charafe-Jauffret, E., Cervera, N., Desplans, J., Parzy, D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2536 · Cited by 297
Significance, detection and markers of disseminated breast cancer cells
Lacroix, M. (2006) · Endocrine-Related Cancer · doi:10.1677/erc-06-0001 · Cited by 293
Basal-like breast carcinomas: clinical outcome and response to chemotherapy
Banerjee, S., Reis-Filho, J. S., Ashley, S., Steele, D., Ashworth, A., Lakhani, S. R., & Smith, I. E. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.033043 · Cited by 290
Abdel-Fatah, T. M. A., Powe, D. G., Hodi, Z., Lee, A. H. S., Reis-Filho, J. S., & Ellis, I. O. (2007) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213368.41251.b9 · Cited by 271
Self-citationTumour-infiltrating macrophages and clinical outcome in breast cancer
Mahmoud, S. M. A., Lee, A. H. S., Paish, E. C., Macmillan, R. D., Ellis, I. O., & Green, A. R. (2012) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200355 · Cited by 268
Self-citationTriple negative breast cancers: Clinical and prognostic implications
Dawson, S. J., Provenzano, E., & Caldas, C. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70013-9 · Cited by 266
The prognostic significance of B lymphocytes in invasive carcinoma of the breast
Mahmoud, S. M. A., Lee, A. H. S., Paish, E. C., Macmillan, R. D., Ellis, I. O., & Green, A. R. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1620-1 · Cited by 261
Self-citationInvasive lobular carcinoma of the breast: Response to hormonal therapy and outcomes
Rakha, E. A., El-Sayed, M. E., Powe, D. G., Green, A. R., Habashy, H., Grainge, M. J., Robertson, J. F. R., Blamey, R., Gee, J., Nicholson, R. I., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.10.009 · Cited by 252
Self-citationHabashy, H. O., Powe, D. G., Staka, C. M., Rakha, E. A., Ball, G., Green, A. R., Aleskandarany, M., Paish, E. C., Douglas Macmillan, R., Nicholson, R. I., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0345-x · Cited by 236
Self-citationMolecular classification of breast cancer: implications for selection of adjuvant chemotherapy
Andre, F., & Pusztai, L. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0636 · Cited by 134
Subtypes of familial breast tumours revealed by expression and copy number profiling
kConFab Investigators, Waddell, N., Arnold, J., Cocciardi, S., da Silva, L., Marsh, A., Riley, J., Johnstone, C. N., Orloff, M., Assie, G., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0653-1 · Cited by 99
Metadata
- Authors
- Abd El‐Rehim, D. M., Ball, G., Pinder, S. E., Rakha, E., Paish, C., Robertson, J. F. R., Macmillan, D., Blamey, R. W., & Ellis, I. O.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2005-06-10
- Volume
- 116
- Issue
- 3
- Pages
- 340-350
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2059272061
- Cited by
- 606
- References
- 43
- FWCI
- 19.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.